Warberg Asset Management LLC boosted its holdings in ZIVO Bioscience, Inc. (NASDAQ:ZIVOW – Get Rating) by 442.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,654 shares of the company's stock after buying an additional 69,034 shares during the period. Warberg Asset Management LLC's holdings in ZIVO Bioscience were worth $51,000 as of its most recent filing with the Securities and Exchange Commission.
ZIVO Bioscience Stock Performance
ZIVO Bioscience stock opened at $0.88 on Wednesday. ZIVO Bioscience, Inc. has a 1-year low of $0.23 and a 1-year high of $1.52. The firm has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $0.77.
Get
ZIVO Bioscience alerts:
About ZIVO Bioscience
(Get Rating)
ZIVO Bioscience, Inc is a Michigan-based biotech/agtech company dedicated to harnessing the immune health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures. The development pipeline includes natural products for use as dietary supplements and functional food ingredients, as well as innovative, biologically derived and synthesized candidates designed to deliver medicinal and pharmaceutical benefits for humans and animals, with a specific focus on modulating the immune and inflammatory response.
Further Reading
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVOW)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Want to see what other hedge funds are holding ZIVOW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIVO Bioscience, Inc. (NASDAQ:ZIVOW – Get Rating).
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
華平資產管理有限責任公司(Warberg Asset Management LLC)最近向美國證券交易委員會(Securities And Exchange Commission)提交的13F檔案顯示,該公司第三季度將其在Zivo Bioscience,Inc.的持股增加了442.0%。該機構投資者持有84,654股該公司股票,在此期間又購買了69,034股。截至最近提交給美國證券交易委員會(Securities And Exchange Commission)的檔案,華寶資產管理有限責任公司持有的Zivo Bioscience股份價值5.1萬美元。
Zivo Bioscience股票表現
Zivo Bioscience的股票週三開盤報0.88美元。Zivo Bioscience,Inc.的一年低點為0.23美元,一年高位為1.52美元。該公司的50日簡單移動均線切入位為0.71美元,200日簡單移動均線切入位為0.77美元。
到達
Zivo生物科學警報:
關於Zivo生物科學
(獲取評級)
Zivo Bioscience,Inc.是一家總部位於密歇根州的生物技術/AgTech公司,致力於利用從其專有藻類培養物中提取的生物活性化合物的免疫健康和營養益處。正在開發的產品包括用作膳食補充劑和功能性食品配料的天然產品,以及旨在為人類和動物提供醫療和製藥益處的創新、生物衍生和合成候選產品,重點是調節免疫和炎症反應。
進一步閱讀
- 免費獲取StockNews.com關於Zivo生物科學的研究報告(ZIVOW)
- 柔順治療公司的差距增加了34%:未來還會有更多的好處嗎?
- 2023年初裁員將如何影響這5只生物科技股?
- Baudax Bio投資者在經歷了70%的飆升後,痛苦是否已經結束?
- 火箭實驗室的首次美國發射將把斯托克送入平流層嗎?
- 現在是時候積極投資國防類股了嗎?
想看看其他對沖基金持有ZIVOW的股票嗎?訪問HoldingsChannel.com獲取Zivo Bioscience,Inc.(納斯達克代碼:ZIVOW-GET Rating)的最新13F備案和內幕交易資訊。
獲得Zivo生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zivo Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。